Noile-Immune Biotech Inc. Logo

Noile-Immune Biotech Inc.

Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.

4893 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区芝大門二丁目12番10号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Noile-Immune Biotech Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company specializes in CAR-T cell therapy aimed at treating solid tumors, a significant challenge in oncology. Its core is the proprietary PRIME (Proliferation-Inducing and Migration-Enhancing) technology, a next-generation platform designed to augment the efficacy of CAR-T cells. Noile-Immune advances its therapeutic pipeline through in-house research and strategic partnerships with academic and corporate entities, with the mission to create transformative treatments for cancer patients.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Noile-Immune Biotech Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-08 09:15
Regulatory News Service
確認書
Japanese 8.1 KB
2025-08-08 09:14
Interim Report
半期報告書-第11期(2025/01/01-2025/12/31)
Japanese 143.9 KB
2025-04-01 09:11
Regulatory News Service
臨時報告書
Japanese 23.5 KB
2025-03-28 05:44
Regulatory News Service
確認書
Japanese 8.2 KB
2025-03-28 05:43
Regulatory News Service
内部統制報告書-第10期(2024/01/01-2024/12/31)
Japanese 21.2 KB
2025-03-28 05:42
Annual Report
有価証券報告書-第10期(2024/01/01-2024/12/31)
Japanese 4.1 MB
2024-10-15 05:07
Regulatory News Service
訂正確認書
Japanese 8.2 KB
2024-10-15 05:06
Regulatory News Service
訂正半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 124.4 KB
2024-08-13 05:02
Interim Report
半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 150.3 KB
2024-08-13 05:00
Regulatory News Service
確認書
Japanese 8.1 KB
2024-05-14 10:07
Regulatory News Service
確認書
Japanese 8.1 KB
2024-05-14 10:05
Quarterly Report
四半期報告書-第10期第1四半期(2024/01/01-2024/03/31)
Japanese 117.7 KB
2024-04-02 06:49
Regulatory News Service
臨時報告書
Japanese 22.2 KB
2024-03-29 06:19
Regulatory News Service
確認書
Japanese 8.2 KB
2024-03-29 06:18
Regulatory News Service
内部統制報告書-第9期(2023/01/01-2023/12/31)
Japanese 21.2 KB

Automate Your Workflow. Get a real-time feed of all Noile-Immune Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Noile-Immune Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Ureru Net Advertising Group Co.,Ltd. Logo
Direct marketing support for D2C e-commerce, boosting sales with patented tech & cloud services.
Japan 9235
Urteste S.A. Logo
Develops non-invasive urine tests to detect cancers early by measuring enzyme activity.
Poland URT
VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan 3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan 6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan 7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea 094850
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden VIVE
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea 310210
WDB coco CO.,LTD. Logo
CRO for pharma & med devices specializing in safety info, PMS & full lifecycle support.
Japan 7079

Talk to a Data Expert

Have a question? We'll get back to you promptly.